论文部分内容阅读
目的:观察allo-PBSCT对恶性血液病的临床疗效。方法:采用经G-CSF动员的同胞HLA相合的异基因外周血干细胞移植,预处理方案采用改良的Bu/Cy方案;GVHD的预防采用CsA联合MMF、MTX,部分患者加用ALG;PGE1联合复方丹参预防VOD。结果:输入CD34+细胞数5.988×106/kg受者体重,全部患者均成功植入,中性粒细恢复至0.5×109/L所需天数为11.68d,血小板恢复至20×109/L所需时间为12.57d,接受CD34+细胞数>5×106/kg者与<5×106/kg者,中性粒细胞与血小板恢复时间差异无统计学意义(P>0.01);Ⅰ~ⅢaGVHD发生率为30.77%,cGVHD的发生率为69.23%,HC发生率11.54%,VOD发生率为0;总死亡率为15.38%,600dDFS为58.96%。结论:allo-PBSCT能提供更快的造血功能恢复,aGVHD的发生率无增加,而cGVHD的发生率较高;allo-PBSCT是治疗恶性血液病较好的治疗手段。
Objective: To observe the clinical effect of allo-PBSCT on hematologic malignancies. Methods: HLA-matched allogeneic peripheral blood stem cell transplantation was performed using sibling mobilized by G-CSF. The modified Bu / Cy regimen was adopted for pretreatment. CsA combined with MMF and MTX was used for the prevention of GVHD. Some patients were treated with ALG. Salvia prevention VOD. Results: The body weight of 5.988 × 106 / kg recipients of CD34 + cells was allograft. All the patients were successfully implanted. The number of days required for recovery of neutrophils to 0.5 × 109 / L was 11.68 days and the platelet count was restored to 20 × 109 / L (12.57d). There was no significant difference in the recovery time of neutrophils and platelets when receiving CD34 + cells> 5 × 106 / kg and <5 × 106 / kg (P> 0.01). The incidence of Ⅰ ~ ⅢaGVHD was 30.77%. The incidence of cGVHD was 69.23%, the incidence of HC was 11.54%, the incidence of VOD was 0, the total mortality was 15.38%, and the 600dDFS was 58.96%. CONCLUSION: Allo-PBSCT can provide faster recovery of hematopoietic function. The incidence of aGVHD does not increase but the incidence of cGVHD is higher. Allo-PBSCT is a better treatment for hematologic malignancies.